- Home
- IBO vs IGC Comparison
IBO vs IGC Comparison
Compare IBO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- IGC
- Stock Information
- Founded
- IBO 2018
- IGC 2005
- Country
- IBO United States
- IGC United States
- Employees
- IBO N/A
- IGC N/A
- Industry
- IBO
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- IGC Health Care
- Exchange
- IBO NYSE
- IGC Nasdaq
- Market Cap
- IBO 22.1M
- IGC 18.0M
- IPO Year
- IBO 2024
- IGC N/A
- Fundamental
- Price
- IBO $0.43
- IGC $0.29
- Analyst Decision
- IBO
- IGC Strong Buy
- Analyst Count
- IBO 0
- IGC 2
- Target Price
- IBO N/A
- IGC $3.88
- AVG Volume (30 Days)
- IBO 9.7M
- IGC 231.3K
- Earning Date
- IBO 05-23-2025
- IGC 02-18-2025
- Dividend Yield
- IBO N/A
- IGC N/A
- EPS Growth
- IBO N/A
- IGC N/A
- EPS
- IBO N/A
- IGC N/A
- Revenue
- IBO N/A
- IGC $1,236,000.00
- Revenue This Year
- IBO N/A
- IGC N/A
- Revenue Next Year
- IBO N/A
- IGC $18.34
- P/E Ratio
- IBO N/A
- IGC N/A
- Revenue Growth
- IBO N/A
- IGC 1.65
- 52 Week Low
- IBO $0.37
- IGC $0.25
- 52 Week High
- IBO $6.17
- IGC $0.63
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- IGC 51.68
- Support Level
- IBO N/A
- IGC $0.27
- Resistance Level
- IBO N/A
- IGC $0.30
- Average True Range (ATR)
- IBO 0.00
- IGC 0.02
- MACD
- IBO 0.00
- IGC 0.00
- Stochastic Oscillator
- IBO 0.00
- IGC 88.00
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.